Screening Library definition

Screening Library means the Xxxxx Compound Library or the Tularik Compound Library.
Sample 1Sample 2
Screening Library shall have the meaning given in the first recital. [ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.
Sample 1Sample 2
Screening Library means a chemical compound library, other than a Focused Library, comprising at least 108 distinct target structures, based on specific agreed scaffold(s) and synthons, prepared by DiCE for use in DiCE internal and external programs, including the Research Program.
Sample 1

Examples of Screening Library in a sentence

  • The Roche Bioscience Screening Library is not part of the Research Compound Library, but may, in Roche Bioscience's sole discretion, be used in HTS against the Targets.

  • The Roche Bioscience Screening Library shall be treated as Roche Bioscience's Confidential Information.

  • The student may appear before the Inquiry Committee on a day, time and place fixed for the meeting with written reply / explanation to the show cause notice served on his/her therein.

  • The Tularik Screening Library is not part of the Research Compound Library, but may be used in HTS against the Targets.

  • Except for the Roche Bioscience Screening License, Tularik shall have no rights to compounds originating from the Roche Bioscience Screening Library unless a Library Compound becomes a Development Compound under Section 5.2. Roche Bioscience shall provide structural information on Validated Hits[ * ].

  • Patents and under Tularik's interest in any Joint Patents (and if the Product is from the Tularik Screening Library, any other Tularik Patent Rights claiming such Library Compound) to develop, make, have made, use, offer to sell, sell or import Products incorporating Roche Bioscience Compounds for the treatment of Roche Bioscience Indications during the term of this Agreement.

  • Subject to Section 5.5, Roche Bioscience hereby grants to Tularik a non-exclusive, royalty-bearing (in accordance with Section 9.5) license to use those compounds in the Roche Bioscience Screening Library to which Roche Bioscience permits Tularik access in Roche Bioscience's sole discretion, which license is solely for HTS and confirmation of "hits" during the Research Term in accordance with the Research Plan (the "Roche Bioscience Screening License").

  • The Tularik Screening Library shall be treated as Tularik's Confidential Information.

  • Subject to Section 5.6, Tularik hereby grants to Roche Bioscience a non-exclusive, royalty-bearing (in accordance with Section 9.5) license to use the Tularik Screening Library solely for HTS and confirmation of "hits" during the Research Term in accordance with the Research Plan (the "Tularik Screening License").

  • Except for the Tularik Screening License, Roche Bioscience shall have no rights to compounds originating from the Tularik Screening Library unless a Library Compound becomes a Development Compound under Section 5.2. Tularik shall provide structural information to Roche Bioscience on Validated Hits [ * ].

Related to Screening Library

  • Screening Test means a drug or alcohol test which uses a method of analysis allowed by the Minnesota Drug and Alcohol Testing in the Workplace Act to be used for such purposes.

  • Library means a code module that cannot be installed or executed separately from an Application and that is developed by You in compliance with the Documentation and Program Requirements only for use with iOS Products, Apple Watch, or Apple TV.

  • Screening means the evaluation process used to identify an individual's ability to perform activities of daily living and address health and safety concerns.

  • Assay means a laboratory analysis of Crude Petroleum to include the following: A.P.I. Gravity, Reid vapor pressure, composition, pour point, water and sediment content, sulfur content, viscosity, distillation, hydrogen sulfide, flash/boiling point and other characteristics as may be required by Carrier.

  • Fluoroscopic imaging assembly means a subsystem in which X-ray photons produce a visual image. It includes the image receptor(s) such as the image intensifier and spot-film device, electrical interlocks, if any, and structural material providing linkage between the image receptor and diagnostic source assembly.

  • Phase I Trial means a clinical trial of a Licensed Product in human patients conducted primarily for the purpose of determining the safety, tolerability and preliminary activity of the Licensed Product, including, without limitation, for determining the maximum tolerated dose, or optimal dose. For purposes of this Agreement, a Phase I trial shall specifically exclude a study in healthy volunteers.

  • Biological Samples means any physical samples obtained from Study Participants in accordance with the Protocol for the purposes of the Study.

  • Phase I Clinical Study means a human clinical study of a product, the principal purpose of which is a preliminary determination of safety in healthy individuals or patients, as described in 21 C.F.R. 312.21(a).

  • Phase I Clinical Trial means a clinical trial conducted in healthy humans or patients, which clinical trial is designed to establish the safety, drug-drug interactions and/or pharmacokinetics of an investigational drug given its intended use, and to support continued testing of such drug in Phase II Clinical Trials.

  • Study means the investigation to be conducted in accordance with the Protocol.

  • Biomarker means a parameter or characteristic in a patient or Patient Sample, the measurement of which is useful (a) for purposes of selecting appropriate therapies or patient populations or monitoring disease susceptibility, severity or state, or monitoring therapies for such patient and/or (b) for predicting the outcome of a particular treatment of such patient.

  • Development Site means any parcel or lot on which exists or which is intended for building development other than the following:

  • Collaboration Compound means any of the following: (a) FG-4592, (b) any HIF Compound (other than FG-4592) that is added to this Agreement pursuant to Section 3.6, and (c) any salts, esters, complexes, chelates, crystalline and amorphous morphic forms, pegylated forms, enantiomers (excluding regioisomers), prodrugs, solvates, metabolites and catabolites of any of the foregoing ((a) or (b)).

  • Step therapy protocol means a protocol or program that establishes the specific

  • Healing arts screening means the testing of human beings using x-ray machines for the detection or evaluation of health indications when such tests are not specifically and individually ordered by a licensed practitioner of the healing arts legally authorized to prescribe such x-ray tests for the purpose of diagnosis or treatment.

  • Field-flattening filter means a filter used to homogenize the absorbed dose rate over the radiation field.

  • Phase II Clinical Study means a human clinical study of a product initiated to determine the safety and efficacy in the target patient population, as described 21 C.F.R. 312.21(b).

  • Phase I Study means a study in humans which provides for the first introduction into humans of a product, conducted in healthy volunteers or patients to obtain information on product safety, tolerability, pharmacological activity or pharmacokinetics, as more fully defined in 21 C.F.R. § 312.21(a) (or the non-United States equivalent thereof).

  • Licensed Compounds means any EZH2 Compound(s) that is:

  • Phase II Trial means a clinical trial of a Licensed Product on patients, including possibly pharmacokinetic and dose ranging studies, the principal purposes of which are to make a preliminary determination that such Licensed Product is safe for its intended use and to obtain sufficient information about such Licensed Product’s efficacy to permit the design of further clinical trials, and generally consistent with 21 CFR §312.21(b), or its successor regulation, or the equivalent in any foreign country.

  • Phase II Clinical Trial means a controlled human clinical study that would satisfy the requirements of 21 CFR 312.21(b), conducted to study the effectiveness and establish the dose range of a Product for a particular Indication in patients with the disease or condition under study, including a Phase IIA Clinical Study or Phase IIB Clinical Study.

  • Backflow prevention device means a safety device used to prevent pollution or contamination of the water supply due to the reverse flow of water from the irrigation system.

  • Phase 2 Clinical Trial means a human clinical trial of a product in any country that would satisfy the requirements of 21 C.F.R. 312.21(b) and is intended to explore a variety of doses, dose response, and duration of effect, and to generate initial evidence of clinical safety and activity in a target patient population, or a similar clinical study prescribed by the relevant Regulatory Authorities in a country other than the United States.

  • Cannabinoid extract means a substance obtained by separating cannabinoids from marijuana by:

  • Phase 3 Trial means a human clinical trial of a Product on a sufficient number of subjects that is designed to establish that a pharmaceutical product is safe and efficacious for its intended use, and to determine warnings, precautions and adverse reactions that are associated with such pharmaceutical product in the dosage range to be prescribed, which trial is intended to support Approval of a Product, as described in 21 C.F.R. 312.21(c) for the United States, or a similar clinical study prescribed by the Regulatory Authorities in a foreign country.

  • Analytical x-ray system means a group of components utilizing x-rays to determine the elemental composition or to examine the microstructure of materials.